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Abstract
The aims of the study were to establish the prevalence of high bone mass (HBM) in a cohort of Spanish postmenopausal
women (BARCOS) and to assess the contribution of LRP5 and DKK1 mutations and of common bone mineral density (BMD)
variants to a HBM phenotype. Furthermore, we describe the expression of several osteoblast-specific and Wnt-pathway
genes in primary osteoblasts from two HBM cases. A 0.6% of individuals (10/1600) displayed Z-scores in the HBM range (sum
Z-score .4). While no mutation in the relevant exons of LRP5 was detected, a rare missense change in DKK1 was found
(p.Y74F), which cosegregated with the phenotype in a small pedigree. Fifty-five BMD SNPs from Estrada et al. [NatGenet
44:491-501,2012] were genotyped in the HBM cases to obtain risk scores for each individual. In this small group of samples,
Z-scores were found inversely related to risk scores, suggestive of a polygenic etiology. There was a single exception, which
may be explained by a rare penetrant genetic variant, counterbalancing the additive effect of the risk alleles. The expression
analysis in primary osteoblasts from two HBM cases and five controls suggested that IL6R, DLX3, TWIST1 and PPARG are
negatively related to Z-score. One HBM case presented with high levels of RUNX2, while the other displayed very low SOX6.
In conclusion, we provide evidence of lack of LRP5 mutations and of a putative HBM-causing mutation in DKK1. Additionally,
we present SNP genotyping and expression results that suggest additive effects of several genes for HBM.
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Introduction
Osteoporosis has a complex genetic background. Bone mineral
density (BMD) is a highly heritable intermediate phenotype that
correlates well with fracture risk [1–6]. BMD is distributed as a
Gaussian curve in the general population, with two small groups
having extremely low or extremely high BMD values at both ends.
These individuals with extreme phenotypes may bear infrequent
and highly penetrant alleles at a few specific loci. Alternatively, the
extreme phenotypes may depend on the presence of a high
number of common variants with low penetrance and additive
effects.
A few individuals with high bone mass (HBM, MIM#601884),
as defined by a sum Z-score .4 (total lumbar spine Z-score + total
femoral neck Z-score), have been reported to bear highly
penetrant missense alleles at the low-density lipoprotein recep-
tor-related protein 5 (LRP5, MIM#603506) locus that are
transmitted in an autosomal dominant way. More than 10 years
ago, two different groups found that LRP5 regulated bone mass
[7,8]. While inactivating mutations in LRP5 were shown to cause
osteoporosis-pseudoglioma syndrome [7], gain-of-function muta-
tions caused a high bone mass (HBM) phenotype [8]. This
phenotype has been associated with the LRP5–G171V mutation in
two independent pedigrees [8,9]. Six additional missense muta-
tions (D111Y, G171R, A214T, A214V, A242T and T253I), all in
the first b-propeller domain of LRP5, were identified in patients
who also showed an increased bone density [10]. The affected
individuals had elevated bone synthesis assessed by serum markers,
but normal bone resorption, bone architecture and serum calcium,
phosphate, PTH and vitamin D levels [8,9]. Significant pheno-
typic heterogeneity was reported, and some affected family
members also had a torus palatinus.
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LRP5 acts as a co-receptor with members of the Frizzled family
to activate the canonical Wnt/b-catenin signalling pathway, which
is crucial for bone formation [11]. This pathway is activated by the
binding of the appropriate Wnt protein to LRP5 and is blocked by
the binding of inhibitors such as Dickkopf-related protein 1
(encoded by DKK1, MIM#605189) and Sclerostin (encoded by
SOST). The HBM-causing mutation prevents the binding of these
two inhibitors. Mutations in SOST are the cause of van Buchem
disease [12] and sclerostosis [13], two pathologies with an
abnormally high bone density. On the other hand, Dkk1+/2 mice
showed a marked increase in bone mass [14].
The prevalence of HBM in the general population has been
estimated as 0.2–1% [8,15,16], but the genetic architecture of this
extreme phenotype remains poorly understood. However, recent
genome-wide association (GWA) analyses and meta-analyses have
established a number of genomic loci that explain differences in
BMD across the general population. In particular, Estrada et al.
[17] identified 56 such genomic loci and showed how they can be
used to calculate risk scores to predict BMD.
In order to explore the genetic constitution of a high bone mass
phenotype, our aims were, first, to establish the prevalence of
HBM in the BARCOS (BARCelona OSteoporosis) cohort of
postmenopausal Spanish women; second, to determine whether
any of the HMB cases carried LRP5 or DKK1 mutations that could
explain the phenotype; and third, to assess whether the HBM cases
were carriers of a low number of risk alleles of 55 autosomal
GWA-identified BMD loci. Also, we took advantage of the
availability of primary osteoblasts from two HBM cases to
characterize the osteoblast RNA in terms of osteoblast-specific
and/or Wnt-pathway genes by comparison with osteoblast RNA
from donors with normal or low BMD.
Materials and Methods
Ethics Statement
Both the Bioethics Committee of Universitat de Barcelona and
the Clinical Research Ethics Committee of Parc de Salud MAR
have emitted a favourable bioethical statement regarding the
present research. Specifically, the protocol for obtention of
peripheral blood from the BARCOS cohort women and the
protocol for the obtention of primary osteoblasts from bone
specimens extracted from knee samples otherwise discarded at the
time of orthopaedic surgery, were approved by both committees.
Written informed consents were obtained from the participants in
both instances.
Study Cohort
The study population (listed in Table 1) included the HBM
cases in the BARCOS cohort (n = 10 unrelated cases). This cohort
of postmenopausal women from the Barcelona area has been
described elsewhere [18,19]. At present time, it includes DXA
values for 1600 women and DNA samples for 1001 of them. Six
additional unrelated female HBM cases were recruited from 3
hospitals of Barcelona, Hospital de Sant Pau (1 case), CETIR (a
private medical services centre specializing in nuclear medicine
and other imaging modalities, 4 cases), and Hospital de
L’Esperanc¸a (1 case). Some relatives of particular cases were also
studied. Blood samples and written informed consent were
obtained in accordance with the regulations of the Clinical
Research Ethics Committee of Parc de Salud MAR. A total of
1600 dual-energy X-ray absorptiometry scans (DXA; QDR 4500
SL; Hologic, Waltham, MA, USA) of the women from this cohort
were analysed in order to pinpoint those HBM cases in which the
sum Z-score (hip plus lumbar spine) was equal to or greater than
four [8]. All DXA measurements were performed prior to any
treatment that could increase bone mass. Pathologic phenotypes
such as osteopetrosis or any other sclerosing bone disorders were
ruled out based on the absence of radiologic alterations in the skull
and long bones, the absence of any fragility fracture and the
absence of any underlying disease. For individuals HBM1, HBM8,
and HBM11, no DNA sample was available.
Sequencing of LRP5 and DKK1
The genomic DNA of n= 13 HBM cases (Table 2) was isolated
from peripheral blood leukocytes using conventional methods. In
all probands, LRP5 exons 2 to 4 (encoding the first beta-propeller
and harbouring all HBM-related mutations described so far) and
exons 9 to 16 (encoding the third and fourth beta-propellers
involved in binding to DKK1), and their intronic flanking regions,
and the four exons and flanking regions of DKK1 were amplified
and sequenced using specific primers. Mutation screening was
performed by direct sequencing using the BigDye v3.1 kit (Applied
Biosystems, Foster City, CA, USA) and the ABI PRISM 3730
DNA Analyzer (Applied Biosystems). Primers and PCR conditions
are listed in Table S1. Nomenclature for DNA variants followed
these reference sequences: NM_002335.2 for LRP5 and
NM_012242.2 for DKK1.
SNP Selection and Genotyping
Out of the 64 SNPs identified by Estrada et al. [17], we chose
55, one for each autosomal locus (listed in Table S2). Genotyping
of the 13 available HBM cases was carried out with a KASPar
v4.0 genotyping system at the Kbioscience facilities (KBioscience,
Herts, UK) using the Kraken allele-calling algorithm [20]. The
genotypes of 1001 BARCOS participants for the same SNPs were
already available, since this cohort was included in the replication
phase of the study by Estrada et al. [17]. One of the SNPs
(rs3790160) gave conflicting results and was eliminated from the
analyses. Quality control was carried out by resequencing 6.28%
Table 1. Z-score values, age and cohort of the participant
women.
Case Sum Z-score LS Z-score HIP Z-score Age Cohort
HBM11, 2 6.1 3.4 2.7 51 BARCOS
HBM2 4.6 3.0 1.6 57 BARCOS
HBM3 4.9 2.5 2.4 55 BARCOS
HBM4 4.5 2.5 2.0 62 BARCOS
HBM5 4.5 2.4 2.1 66 BARCOS
HBM6 5.1 2.6 2.5 52 BARCOS
HBM7 4.6 2.5 2.1 61 BARCOS
HBM82 7.9 4.0 3.9 55 BARCOS
HBM9 7.0 4.6 2.4 66 BARCOS
HBM10 5.1 2.8 2.3 75 BARCOS
HBM112 6.8 3.8 3.0 55 HSANTPAU
HBM12 6.4 3.8 2.6 59 CETIR
HBM13 5.2 2.6 2.6 67 CETIR
HBM14 6.0 3.7 2.3 64 CETIR
HBM15 4.5 2.4 2.1 54 CETIR
HBM16 5.3 3.6 1.7 77 HESP
1Deceased during the course of the study.
2No DNA sample available.
doi:10.1371/journal.pone.0094607.t001
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of the samples. The readings showed full concordance between the
two techniques.
Genetic Risk Allele Analysis
Fifty-five SNPs previously described to be associated with BMD
at GWA significance [17] were genotyped in the 13 HBM cases
and the genetic risk score for each individual was then calculated
by taking into account both the number of risk alleles and the
relative effect of each SNP on BMD, as carried out by Estrada et
al. [17]. This calculation was also performed for 1001 individuals
in the BARCOS cohort with available SNP genotype and LS-
BMD data. Briefly, the genotype of each SNP was transformed
into a risk score by taking into account the effects estimated by the
authors and listed in their Supplementary Table 9. The effect size
(beta parameter or slope) is the BMD decrease due to the presence
of one copy of the risk allele. The scores for homozygotes for the
risk allele were 2x the effect size; scores for heterozygotes were 1x
the effect size; and the scores for homozygotes for the alternative
allele were zero. For each individual, the risk scores of all SNPs
were summed up to obtain a global risk score, which was then
normalized by dividing it by the mean effect size of BARCOS.
Normalized global risk scores were sorted into five bins, as
described in Estrada et al. [17]. Missing genotypes within
BARCOS cohort individuals and also within HBM probands
were solved by replacing them by the mean of the corresponding
SNP scores in BARCOS. This strategy would attenuate the
variance of the overall group [21].
Primary Osteoblast Isolation and Cell Culture
Primary osteoblast (hOB) cells of postmenopausal women were
available from bone specimens extracted from knee samples that
would otherwise have been discarded at the time of artroplasty.
Both informed consent and BMD values were obtained from the
donors. Two of them were patients HBM10 and HBM16. Five
female donors with sum Z-score values (and ages) of 2.4 (85 y), 1.2
(74 y), 0.4 (79 y), 20.7 (70 y) and 22.2 (61 y), were used as
controls. The bone tissue used was obtained from a region at least
2 cm apart from the subchondral and the osteochondral plates far
from the described 6 mm layer of trabecular bone below the above
mentioned plates [22]. With this we aimed to minimize the
potential issues of using osteoblastic cells located close to the
damaged joint (given the known relationship and mutual
influences between the inflamed cartilage and adjacent bone cells)
and the alterations in phenotype and gene expression of the
osteoblasts in this zone [23,24]. The hOB cells were obtained, as
described previously [25,26]. Briefly, the trabecular bone was
separated and cut into small fragments, washed in phosphate
buffered solution (PBS) to remove non-adherent cells, and placed
on a petri dish. Samples were incubated in Dulbecco’s Modified
Eagle Medium (DMEM; Gibco; Invitrogen, Paisley, UK),
supplemented with sodium pyruvate (1 mM), L-glutamine
(1 mM), 1% penicillin/streptomycin, 10% fetal calf serum (FCS),
0.4% fungizone and 1% ascorbic acid. This allowed osteoblastic
precursor cells to migrate from the fragments and proliferate. After
confluence, cells were trypsinized and cultured in the same
medium. When sub-confluence was reached again, the medium
was aspirated and fresh medium with 10% serum or 0.1% bovine
serum albumin was added. Forty-eight hours later, the medium
was aspirated, cells were rinsed with phosphate-buffered saline,
and the RNA was extracted. Standard histochemistry or
quantitative PCR tests to measure alkaline phosphatase or
osteocalcin expression, respectively, were used to confirm the
osteoblastic nature of the cells, as described in [27].
RNA Extraction, cDNA Synthesis and Real-time PCR
Total cell RNA was extracted using the High Pure RNA
Isolation Kit (Roche Diagnostics, Mannheim, Germany) in
accordance with the manufacturer’s instructions. Two micrograms
of total RNA were reverse transcribed using random primers of
the High Capacity cDNA RT Kit (Applied Biosystems) in
accordance with the manufacturer’s instructions. The real-time
PCR (qPCR) reactions were performed in a final volume of 10 ml
using 20 ng of each cDNA, which was used as template for each
well in the RealTime ready Custom Panel 384 (Roche Diagnos-
tics). This custom panel included 88 genes selected by us, taking
into account, among other sources, the sites recently highlighted
by GWA analyses, in particular those in Estrada et al. [17] and
Duncan et al. [28]. All qPCR reactions for each sample were
performed in triplicate with the LightCycler 480 Real-Time PCR
System (Roche Diagnostics). Beta-2-microglobulin (B2M) was
chosen as the reference gene because of its minimum coefficient
of variation between samples.
Validation of the 11 genes with positive results in the expression
analysis described previously was performed with new assays
designed using the online ProbeFinder software (Roche Diagnos-
tics). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
18 S ribosomal (18 S) were tested as possible reference genes, and
GAPDH was selected. For this validation step, samples from three
additional control individuals were included in the analysis. Again,
all qPCR reactions for each sample were performed in triplicate
with the LightCycler 480 Real-Time PCR System (Roche
Diagnostics).
Table 2. Genotypes at LRP5 and DKK1.
LRP5 exonic SNPs
DKK1 exonic
changes
Case p.V667M1 p.A1330V1 p.V1119V1 Others1 p.A106A1 Variant
HBM2 - - Het. p.E644E Het. -
HBM3 - - Het. p.N705N Homo. -
HBM4 - Het. Het. p.N740N Het. -
HBM5 - - Het. p.E644E - -
HBM6 - - - - Homo. -
HBM7 - - Het. p.N740N - -
HBM9 - Het. Het. - Het. -
HBM10 - - Het. - - -
HBM12 - - Het. p.E644E Het. -
HBM13 Het. Het. Het. p.N740N Het. -
HBM14 - Het. Het. p.N740N Het. -
HBM15 - - - - - p.Y74F2
HBM16 - - - p.E644E - -
1Corresponding reference sequences, rs-numbers and MAFs are: LRP5
(NM_002335.2): p.E644E (rs2277268. 0.06); p.V667 (rs4988321. 0.03); p.N705N
(rs145456776. ,0.01); p.N740N (rs2306862. 0.15); p.V1119V (rs556442. 0.28);
p.A1330V (rs3736228. 0.13). DKK1 (NM_012242.2): p.A106A (rs2241529. 0.46). All
LRP5 variants listed under ‘‘Others’’. as well as the DKK1 p.Y74F were found in
heterozygous state.
2A novel missense change is indicated in bold. Het.: heterozygous for the
variant; Homo.: homozygous for the minor allele; NA: not available; -:
homozygous for the reference allele.
doi:10.1371/journal.pone.0094607.t002
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Statistical Analysis
Linear regression was analysed by first testing the most
important assumptions (normality and homoscedasticity). Calcu-
lations were performed with SPSS v11.5 (SPSS, Chicago, IL,
USA). To test skewness (or asymmetry of a distribution) of the
genetic risk distributions of the HBM cases and the BARCOS
controls, we used the robust medcouple (MC) measure, with left
and right tail weight measures (LMC and RMC), and constructed
the MC-LR confidence interval [29].
Results
HBM Prevalence in the BARCOS Cohort and Features of
the HBM Cases
In total, 1600 DXA scans were analysed across the BARCOS
cohort. Those cases in which the sum Z-score was equal to or
greater than four were considered HBM cases and further
analysed. Pathologic phenotypes were ruled out based on a more
in-depth examination of the medical history, a physical examina-
tion and a radiologic study. In the BARCOS cohort, 10 cases
(0.63% of individuals) fulfilled this HBM criterion. Six additional
HBM cases were recruited elsewhere (see Materials and Methods).
Z-score values, age and cohort for all HBM cases are listed in
Table 1.
Search for Mutations in LRP5 and DKK1
Exons 2 to 4 of LRP5, which encode the first beta-propeller of
the protein, and in which HBM mutations have previously been
described, were sequenced in the 13 HBM cases with available
DNA sample. Next, exons 9 to 16 were analysed, since they
encode beta-propellers 3 and 4, which have been described as
binding regions for the LRP5 inhibitor DKK1. No novel or
previously described causing mutations were found in any of these
exons. The missense LRP5 polymorphisms p.V667M (rs4988321)
and p.A1330V (rs3736228), associated with BMD in GWA
studies, together with other silent exonic variants found in the
HBM individuals, are shown in Table 2. Their frequencies in
HBM cases were similar to those found in the general population
(dbSNP; http://www.ncbi.nlm.nih.gov/SNP/). Regarding DKK1,
the four exons and flanking regions were amplified and sequenced
in the 13 HBM cases. One previously undescribed heterozygous
missense change (p.Y74F) and an exonic silent polymorphism were
found in different individuals (Table 2). The p.Y74F was not
present in the 1000 genomes database, while the tyrosine 74 and
adjacent residues were found to be conserved in the Dkk1
sequences of primates, rodents and cows, but not in C. lupus or D.
rerio (Fig. 1A). PolyPhen-2 (HumDiv) and SIFT scores for this
missense change were as follows: 0.48 (possibly damaging) and
0.38 (tolerated), respectively. Examination of the offspring of case
HBM15 revealed a cosegregation of this mutation with the HBM
phenotype (Fig. 1B). The daughter was found to be an HBM case
(sum Z-score: 4.9) and was heterozygous for the mutation, while
her brother had a normal sum Z-score value (0.5) and did not
carry this DNA change.
Analysis of 55 Bone Mineral Density Loci
Figure 2A shows the distribution of the BARCOS individuals
into five different osteoporosis risk score bins (bars) and the mean
LS-BMD value for each bin (triangles). Risk scores were derived
from the number and effect of the BMD-associated SNPs
described in Estrada et al. [17] (see Methods). As expected, a
decrease in BMD values was observed as the genetic risk score
increased (Pearson correlation coefficient =20.972, p = 0.0057,
r2 = 0.94). Figure 2B shows a similar graph for the 11 HBM
individuals for which genotyping was successful (two of the HBM
cases -HBM14 and HBM16- had to be discarded because of sub-
optimal genotyping results). The frequency distribution shows a
shift towards the lower genetic risk score bins. Again, BMD values
(measured as Z-scores) decreased as genetic risk scores increased,
with the exception of one individual (HBM9), who presented the
maximum BMD value (Z-score = 7) and the largest genetic risk
score. Interestingly, the HBM phenotype in the family of HBM9
seems to segregate as a discrete trait: the mother is also a HBM
individual (sum Z-score = 4.4), while her eldest brother is not
(Fig. 2C). A correlation analysis between risk scores and Z-scores
of the 11 HBM individuals was not possible due to the small
sample size, since linear regression assumptions were not fulfilled.
To compare the two distributions their skewness was analyzed.
MC-LR 95% confidence intervals for skewness [(20.193, 0.116)
for Fig 2A and (21.528, 0.740) for Fig 2B] pointed to a loss of
symmetry for Fig 2B. However the intervals did overlap, due to the
limited sample size of the HBM group. Thus, significant
differences between the two groups could not be formally
demonstrated.
Expression Analysis of 88 Bone-development and/or
Wnt-pathway Genes
A transcriptomic analysis by qPCR was carried out in primary
osteoblast samples from two HBM and two age- and gender-
matched control individuals that were obtained after knee-
replacement orthopaedic surgery. Because of the small sample
size, the approach was only meant to be descriptive. In a first step,
11 out of 88 bone-development and/or Wnt-pathway genes were
selected (Table 3) due to differences above or below 2-fold in mean
expression level between the two HBM cases and the two control
individuals. Subsequently, these 11 genes were re-analysed using
samples from the two HBM and five control individuals (the initial
2 controls, whose Z scores were negative, and 3 new ones with Z-
scores of 0.4, 1.2 and 2.4). Because the sum Z-scores of the control
individuals were scattered across a wide range of values, expression
levels were plotted against sum Z-scores and we observed that
TWIST, ILR6, DLX3 and PPARG displayed a trend of correlation
(Figure 3,A–D). R2 values for the four genes were 0.676, 0.895,
0.807 and 0.461, respectively. However, due to the small sample
size, linear regression assumptions were not fulfilled. Thus, no p-
values are provided. We also observed that for SOX6 and RUNX2,
one of the HBM samples (but not the other) presented an
expression level that was 5-fold decreased or increased, respec-
tively, compared with controls (Fig. 3E and 3F, respectively).
Discussion
In this study we established that the prevalence of HBM in a
Spanish cohort of postmenopausal women is 0.63%. None of the
HBM individuals had mutations in the relevant exons of the LRP5
gene that could explain their phenotype. One individual had a
rare missense change in DKK1 (p.Y74F). The results of the analysis
of 55 osteoporosis-predisposing SNPs pointed to an inverse
correlation between risk alleles and BMD in this group of HBM
women, with the exception of one case with the highest BMD
value and the highest risk score. Finally, the results of an
expression analysis in primary osteoblasts showed a negative trend
between Z-scores and mRNA levels of TWIST1, IL6R, DLX3and
PPARG.
There are few studies that describe the prevalence of HBM in
the general population. In a recent one [15], the authors studied a
UK DXA-scanned population in which the prevalence of HBM
was 0.2% of individuals. The lower prevalence (0.2% versus our
Genetic Analysis of High Bone Mass
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0.6%) may be due to differences in the study design, including the
definition of HBM, which was stricter in their study. All HBM-
related LRP5 mutations identified to date are located in the first
beta-propeller of the protein [10], while the mutations that cause
osteoporosis-pseudoglioma syndrome and exudative vitreoretino-
pathy are found all over the gene [30]. In our mutational analysis
of exons coding for the first beta-propeller (and for the third and
fourth, which have been described as binding regions for DKK1
[31]) no mutations were detected in the 13 HBM individuals
analysed. Our results are in agreement with those published by
Duncan et al. [32], who pointed out that ,2% of their HBM cases
were due to mutations on exons 2–4 and intron/exon boundaries
of the LRP5 gene, after analysing 98 patients.
We also analysed the DKK1 gene under the hypothesis that loss-
of-function mutations in this gene could have the same effect as
gain-of–function mutations in LRP5. In this regard, it has been
shown that bone mass was inversely proportional to Dkk1 levels in
mice [33], and there are therapies under development based on
DKK1 inhibition to increase bone mass (reviewed in Ke et al. [34]).
We found a missense change (p.Y74F) in heterozygosis in one
HBM individual. We have gathered some evidence that supports a
causative role for this mutation. The change affects a conserved
residue and it is predicted to be possibly damaging. Additionally, it
cosegregates with HBM in the nuclear pedigree of case HBM15.
In humans, the only report on DKK1 mutations is by Korvala et al.
[35], who recently suggested that a mutation in DKK1 may
predispose individuals to primary osteoporosis. No mutations were
found in the HGMD Professional 2012.4 database (released 29
March 2013), and a limited number of very rare missense changes
(31) were found in the 1000 genomes database (released 13
December 2012); eleven of these are predicted to be deleterious by
SIFT and probably damaging by PolyPhen. Whether these
changes, or the p.Y74F described in this paper, are associated
with a HBM phenotype remains an interesting open question,
which will require functional analyses to be confirmed.
To test whether HBM could be explained by a polygenic
additive effect of susceptibility loci, we chose to genotype the
GWA-discovered BMD loci defined by Estrada et al. [17]. We
were able to use the BARCOS cohort information for these same
loci as a framework for comparison. We would expect HBM
individuals to bear a high number of protective alleles or a low
number of risk alleles. As seen in Figure 2, the distribution of
genetic risk scores for the HBM cases shifted towards lower risk,
with the mode bin set at 44–48 instead of 48–52 and lost
symmetry. However, due to the limited number of HBM cases,
statistical significance was not achieved and, thus, no significant
differences between the small cohort of individuals with HBM and
the BARCOS cohort could be demonstrated.
Additionally, Z-score values decreased as genetic risk scores
increased, suggesting that common variation is playing a role in
determining HBM. However, we note that the only HBM
individual falling into the highest risk score bin (HBM9) was the
one with the highest Z-score and such a contradictory fact might
indicate the existence of a highly penetrant and probably rare
Figure 1. Mutation p.Y74F of DKK1 may be responsible for high bone mass in family HBM15. (A) Alignment of a partial human DKK1
sequence with those of several vertebrates. The tyrosine-74 residue is boxed. (B) Pedigree of case HBM15 (arrow): filled symbols indicate a high bone
mass phenotype. Numbers inside symbols are sum Z-score values.
doi:10.1371/journal.pone.0094607.g001
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Figure 2. Distribution of genetic risk scores in BARCOS and in the HBM group. Distributions of genetic risk scores among 1001 BARCOS
individuals (A) and 11 HBM probands (B), and their relationships with BMD or Z-score values, are shown. Histograms describe counts of individuals in
each genetic score category (left axis scale); (A) From left to right, exact numbers of individuals in each bin are: 88, 222, 355, 238 and 98. Triangles
(right axis scale) represent LS-BMD means and vertical bars depict their standard errors; (B) Diamonds represent mean Z-score values. (C) Pedigree of
family HBM9. Arrow indicates the proband HBM9; filled symbols represent presence of the HBM phenotype; numbers below symbols denote sum Z-
scores; NA: not available.
doi:10.1371/journal.pone.0094607.g002
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protective allele counterbalancing the additive effect of the risk
alleles. The HBM phenotype of this individual might be a
Mendelian trait due to an as-yet unidentified gene. Altogether,
these results are consistent with the coexistence of both polygenic
and Mendelian cases of HBM, which would then be a
heterogeneous trait.
To gain further insight into specific genes that might be involved
in HBM, we undertook a descriptive transcriptomic study of two
HBM cases for which we had access to primary osteoblast cultures.
When expression levels were compared between the HBM cases
and five controls, it was interesting to find four genes that
presented mRNA levels displaying a negative trend with BMD
Table 3. Eleven genes selected from the RealTime Custom
Panel1.
Wnt-pathway genes Bone biology genes
FZD3 BMP4 IL6R SOX6
SOST COL10A1 PPARG SP7 (OSX)
DLX3 RUNX2 TWIST1
1Those displaying at least a two-fold difference between the mean expression levels
of HBM10 and HBM16 and the mean of the two controls with negative Z-scores.
doi:10.1371/journal.pone.0094607.t003
Figure 3. Analysis of mRNA levels of several candidate genes in relation to BMD levels. (A–D) Trend of correlation between Z-score values
and gene expression levels of (A) TWIST1, (B) IL6R, (C) DLX3 and (D) PPARG. (E) One of the HBM samples presented an expression level of SOX6 5-fold
decreased in relation to the mean of five control individuals. (G) The other HBM sample presented an expression level of RUNX2 that was 6-fold
increased.
doi:10.1371/journal.pone.0094607.g003
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(TWIST1, IL6R, DLX3 and PPARG). Two other genes had one of
the two HBM samples with outlier mRNA levels: RUNX2 was 6-
fold elevated in one HBM sample, while SOX6 was 5-fold reduced
in the other HBM sample. In spite of the evident low sample size,
it is tempting to speculate that these genes (among others) may
play a role in HBM, acting in an additive way.
The limitations of this study include the small sample size of
HBM cases, which precluded reaching significance. Replication in
other cohorts will be necessary to confirm some of our results. This
is particularly important in the expression analysis, where the
number of analysed individuals was modest because of the great
difficulty in finding primary human osteoblasts. It may be argued
that the fact that the donors suffered from arthritis is a
confounding factor. However, all donors were affected with this
condition regardless of their BMD and it might be assumed that
the effect of artritis would be similar in all of the samples. To
minimize the impact of arthritis, caution was taken to obtain the
osteoblasts from locations far away from the lesion. However, a
systemic effect of arthritis cannot be totally ruled out.
In conclusion, to our knowledge, this genomic and transcrip-
tomic analysis of HBM is the first report of its kind. By combining
both strategies, it was possible to gain a deeper insight into the
genetic makeup of HBM. It includes suggestive evidence of genetic
heterogeneity based on the observation of additive effects of
several genes, on one hand, and monogenic cases not caused by
LRP5, on the other. DKK1, possibly responsible for one of these
monogenic cases, would be a novel HBM gene. Future studies in
enlarged cohorts may confirm the relevance of the genes described
here, some of which might be therapeutic targets for osteoporosis.
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